Avalo Therapeutics Ownership | Who Owns Avalo Therapeutics?

Avalo Therapeutics Ownership Summary

Avalo Therapeutics is owned by 58.70% institutional investors, 3.48% insiders, and 37.83% retail investors. Bvf inc/il is the largest institutional shareholder, holding 12.51% of AVTX shares. T. Rowe Price Small-Cap Stock is the top mutual fund, with 2.77% of its assets in Avalo Therapeutics shares.

AVTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Avalo Therapeutics	58.70%	3.48%	37.83%
Sector	Healthcare Stocks	232.86%	10.65%	-143.51%
Industry	Biotech Stocks	382.13%	10.41%	-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bvf inc/il	1.36M	12.51%	$17.23M
Orbimed advisors	1.35M	12.46%	$17.15M
Point72 asset management	1.05M	9.73%	$13.40M
Affinity asset advisors	1.01M	9.29%	$12.79M
Nantahala capital management	1.24M	8.82%	$22.43M
Ubs group	1.14M	8.52%	$17.05M
Caligan partners lp	833.33K	7.69%	$10.59M
Ra capital management	662.97K	6.12%	$8.43M
Vanguard group	804.08K	5.74%	$14.60M
Tcg crossover management	483.00K	4.46%	$6.14M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Velan capital investment management lp	263.64K	3.15%	$3.35M
Superstring capital management lp	188.08K	2.36%	$2.39M
Caligan partners lp	833.33K	1.39%	$10.59M
Ally bridge group (ny)	178.10K	1.38%	$2.26M
Silverarc capital management	524.44K	1.32%	$9.52M
Patient square capital lp	311.97K	1.21%	$5.67M
Affinity asset advisors	1.01M	1.11%	$12.79M
Nantahala capital management	1.24M	0.74%	$22.43M
Bvf inc/il	1.36M	0.70%	$17.23M
Allostery investments lp	9.00K	0.57%	$44.91K

Top Buyers

Holder	Shares	% Assets	Change
Point72 asset management	1.05M	0.02%	1.05M
Caligan partners lp	833.33K	1.39%	833.33K
Ubs group	1.14M	0.00%	664.16K
Soleus capital management	441.98K	0.30%	441.98K
Affinity asset advisors	1.01M	1.11%	398.35K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	662.97K	0.10%	-270.00K
Silverarc capital management	524.44K	1.32%	-196.49K
Deep track capital, lp	-	-	-144.60K
Exome asset management	-	-	-100.04K
Allostery investments lp	9.00K	0.57%	-98.14K

New Positions

Holder	Shares	% Assets	Change	Value
Point72 asset management	1.05M	0.02%	1.05M	$13.40M
Caligan partners lp	833.33K	1.39%	833.33K	$10.59M
Soleus capital management	441.98K	0.30%	441.98K	$8.03M
Adage capital partners gp	258.77K	0.01%	258.77K	$3.29M
Ameriprise financial	213.57K	0.00%	213.57K	$2.71B

Sold Out

Holder	Change
Raymond james financial	-1.00
Sbi securities	-23.00
Simplex trading	-748.00
Bit capital gmbh	-1.93K
Hrt financial lp	-10.29K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	41	-41.43%	8,217,986	-46.35%	58	0.29%	30	-36.17%	4	-50.00%
Sep 30, 2025	69	97.14%	14,834,685	89.14%	136	2.61%	47	261.54%	8	-33.33%
Jun 30, 2025	35	6.06%	7,843,040	-4.99%	72	1.18%	13	-13.33%	12	200.00%
Mar 31, 2025	33	-	8,255,057	9.62%	78	1.52%	15	-11.76%	4	33.33%
Dec 31, 2024	33	17.86%	7,530,521	13.12%	71	1.07%	17	30.77%	3	200.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price Small-Cap Stock	678.82K	2.77%	678.82K
T. Rowe Price US Small-Cap Core Equity	678.82K	2.77%	678.82K
Vanguard Total Stock Mkt Idx Inv	537.79K	2.19%	-
FIAM Small Cap Core CIT Cl B	522.10K	1.95%	522.10K
T. Rowe Price Small-Cap Value	379.09K	1.55%	379.09K
T. Rowe Price Instl Small-Cap Stock	348.39K	1.42%	348.39K
Fidelity Advisor Biotechnology I	358.30K	1.34%	-
T. Rowe Price U.S. SC Core Eq Tr-D	322.06K	1.31%	322.06K
Kennedy Micro Cap	247.47K	1.01%	247.47K
T. Rowe Price U.S. SC Value Eq Tr-D	247.44K	1.01%	247.44K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 06, 2026	VARKI PAUL	Chief Legal Officer	Sell	$210.03K
May 06, 2026	VARKI PAUL	Chief Legal Officer	Sell	$706.84K
May 06, 2026	VARKI PAUL	Chief Legal Officer	Sell	$102.78K
May 06, 2026	VARKI PAUL	Chief Legal Officer	Sell	$484.54K
May 06, 2026	VARKI PAUL	Chief Legal Officer	Sell	$9.48K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	25
2026 Q1	-	1
2025 Q4	-	2
2025 Q3	-	-
2025 Q2	-	-

AVTX Ownership FAQ

Who Owns Avalo Therapeutics?

Avalo Therapeutics shareholders are primarily institutional investors at 58.70%, followed by 3.48% insiders and 37.82% retail investors. The average institutional ownership in Avalo Therapeutics's industry, Biotech Stocks , is 382.13%, which Avalo Therapeutics falls below.

Who owns the most shares of Avalo Therapeutics?

Avalo Therapeutics’s largest shareholders are Bvf inc/il (1.36M shares, 12.51%), Orbimed advisors (1.35M shares, 12.46%), and Point72 asset management (1.05M shares, 9.73%). Together, they hold 34.71% of Avalo Therapeutics’s total shares outstanding.

Does Blackrock own Avalo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Avalo Therapeutics.

Who is Avalo Therapeutics’s biggest shareholder by percentage of total assets invested?

Velan capital investment management lp is Avalo Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.15% of its assets in 263.64K Avalo Therapeutics shares, valued at 3.35M$.

Who is the top mutual fund holder of Avalo Therapeutics shares?

T. Rowe Price Small-Cap Stock is the top mutual fund holder of Avalo Therapeutics shares, with 2.77% of its total shares outstanding invested in 678.82K Avalo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools